



Perma-Fix Medical S.A. Announces Plans to List on NASDAQ

WROCLAW and ATLANTA – April 4, 2016 – Perma-Fix Medical S.A (WAR: PFM), today announced that it plans to list on the NASDAQ market in the United States later this year. Current investors will maintain their same equity ownership percentage in any new corporate structure prior to any potential future capital raise in the U.S. The Company will provide further announcements regarding the anticipated timing of a NASDAQ listing based on market conditions in the U.S.

Dr. Louis F. Centofanti, Chairman of Perma-Fix Medical S.A, commented: "We have made tremendous progress advancing our new process to produce Technetium-99m (Tc-99m), the most widely used medical isotope in the world. We have had our process independently validated at both the University of Missouri Research Reactor in the U.S. and at POLATOM in Europe. We subsequently received an investment and signed a long-term supply agreement with Digirad (NASDAQ: DRAD), the leading user of Tc-99m in the U.S. We believe we have mitigated the technology, regulatory, and commercial risks related to our technology. Despite all these advances, we believe our stock is dramatically undervalued. We believe the NASDAQ would provide us greater access to North American and global healthcare and life science investors. We appreciate the support we have received from our shareholders and we strongly believe this path will provide our current and future investors a better path to maximize shareholder value."

About Perma-Fix Medical S.A.

Perma-Fix Medical S.A. was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszewska or David K. Waldman
Crescendo Communications Europe Sp. z o.o
Tel: + 48 693 354 580
Email: pfm@crescendo-ir.com